Skip to main content
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NRXP ISIN · US0894821034 LEI · 5493003FN4CLS0670T77 US Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2026-06-04 Capital/Financing Update
Country US United States of America
Listing US NRXP

About NRX Pharmaceuticals, Inc.

https://www.nrxpharma.com/

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system (CNS) disorders. The company focuses on addressing high unmet medical needs for patients with life-threatening conditions, particularly suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). Its development pipeline is based on its N-methyl-D-aspartate (NMDA) receptor platform. The lead candidate, NRX-101, is an investigational oral medication for suicidal bipolar depression that has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA). Other key programs include NRX-100 for suicidal ideation and KETAFREE™, a preservative-free ketamine product.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 92% confidence The document is a Form 8-K current report describing NRx Pharmaceuticals’ entry into an underwriting agreement and public offering of equity, including pricing and closing details. This is a direct update on the company’s fundraising and capital issuance. Under our taxonomy, such announcements belong to the Capital/Financing Update category (CAP).
2026-06-04 English
FORM 424B5
Share Issue/Capital Change Classification · 92% confidence The document is a Form 424B5 Prospectus Supplement filed under Rule 424(b)(5) for the issuance of 5,714,286 shares of common stock, describing the public offering price, underwriting discounts, use of proceeds and other terms of the share issuance. This is not an annual or quarterly report, an earnings release, or a management discussion; rather, it is the actual offering document for new equity shares. That fits the definition of a share issue/capital change announcement (Code SHA).
2026-06-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report (Item 8.01) announcing that the company intends to offer shares in an underwritten public offering. This is a financing activity update, matching the Capital/Financing Update category rather than a general regulatory filing or other categories.
2026-06-02 English
FORM 424B5
Capital/Financing Update Classification · 88% confidence The document is a Form 424B5 Preliminary Prospectus Supplement filed under SEC Rule 424(b)(5) related to an equity offering of common stock. It is not an annual or interim report, nor an earnings release or proxy statement. Instead, it details terms of a fundraising (underwritten share offering) and product use of proceeds, fitting the Capital/Financing Update category.
2026-06-02 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
10-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)
Annual Report
2026-03-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.